<DOC>
	<DOCNO>NCT02234050</DOCNO>
	<brief_summary>The aim study collect data activity , toxicity quality life trabectedin therapy patient recurrent high-grade meningioma .</brief_summary>
	<brief_title>Trabectedin Recurrent Grade II/III Meningioma</brief_title>
	<detailed_description>This randomize open label multicenter comparative phase II trial . The objective study investigate whether trabectedin demonstrate sufficient antitumor activity recurrent grade II III justify investigation phase III adjuvant therapy newly diagnose disease resection radiotherapy .</detailed_description>
	<mesh_term>Meningioma</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>Patient selection criterion Age 18 old Histological diagnosis WHO grade II ( chordoid meningioma , clear cell meningioma , atypical meningioma ) WHO grade III ( papillary meningioma , rhabdoid meningioma , anaplastic/malignant meningioma ) accord WHO 2007 classification . Radiologically documented progression exist tumor ( growth &gt; 25 % last year ) appearance new lesion ( include intra extracranial manifestation ) No option local therapy ( resection radiotherapy ) maximal feasible surgery radiotherapy No prior systemic antineoplastic therapy meningioma Measurable disease ( 10 x10 mm ) cranial MRI 2 week prior randomization . WHO performance status 02 Adequate liver , renal hematological function within 4 week prior randomization , define : Neutrophils ≥ 1.5 x 109/L , hemoglobin ≥ 9 g/dL hemoglobin ≥ 5.6 mmol/L , platelet ≥ 100 x 109/L Total Bilirubin ≤ 1 x ULN , SGPT/ALT SGOT/AST ≤ 2.5 x ULN Alkaline phosphatase ≤ 2.5 x ULN ; alkaline phosphatase &gt; 2.5 ULN , ALP hepatic isoenzyme and/or 5nucleotidase and/or gamma glutyamyltransferase ( GGT ) must within normal range Albumin ≥ 30 g/L Serum creatinine ≤ 1.5 x ULN Creatinine clearance &gt; 30 ml/min calculate Cockcroft Gault formula ( see Appendix E ) Creatine phosphokinase ( CPK ) ≤ 2.5 x ULN Normal cardiac function ( LVEF assess MUGA ECHO within normal range institution ) , normal 12 lead ECG ( without clinically significant abnormality ) . The follow unstable cardiac condition allow : Congestive heart failure Angina pectoris Myocardial infarction within 1 year registration/randomization Uncontrolled arterial hypertension define blood pressure ≥ 150/100 mm Hg despite optimal medical therapy Arrhythmias clinically significant Life expectancy least 9 week No history invasive malignancy within last 5 year ( except adequately treat nonmelanoma skin cancer , clinicaly localize low risk prostate cancer , adequately treated cervical intraepithelial neoplasia ) No serious illness medical condition , specifically : active infectious process ; chronic active liver disease , include chronic hepatitis B , C cirrhosis No concomitant use investigational agent phenytoin Women child bear potential ( WOCBP ) must negative serum ( urine ) pregnancy test within 72 hour prior first dose study treatment . Women childbearing / reproductive potential use adequate birth control measure , define investigator , study treatment period least 3 month last study treatment . Men fertile must use effective contraception treatment trabectedin 5 month thereafter . A highly effective method birth control define one result low failure rate , i.e . le 1 % per year , use consistently correctly . Female subject breastfeed discontinue nursing prior first dose study treatment 3 month last study treatment . No known MRI CT , include contrast medium , contraindication Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial Patients buffer range normal value +/ 5 % hematology +/ 10 % biochemistry acceptable . A maximum +/ 2 day timeline may acceptable Before patient randomization , write informed consent must give accord ICH/GCP , national/local regulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Grade 2 Chordoid meningioma</keyword>
	<keyword>Grade 2 Clear cell meningioma</keyword>
	<keyword>Grade 2 Atypical meningioma</keyword>
	<keyword>Grade 3 Papillary meningioma</keyword>
	<keyword>Grade 3 Rhabdoid meningioma</keyword>
	<keyword>Grade 3 Anaplastic meningioma</keyword>
	<keyword>Grade 3 Malignant meningioma</keyword>
</DOC>